Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Chaudhury, Sidhartha ^a   Regules, Jason A ^b   Darko, Christian A ^c   Dutta, Sheetij ^c   Wallqvist, Anders ^a   Waters, Norman C ^c   Jongert, Erik ^d   Lemiale, Franck ^e   Bergmann Leitner, Elke S ^c  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d GSK   (Belgium)

^e PATH Malaria Vaccine Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; IMMUNOGLOBULIN G; MALARIA VACCINE; OPSONIN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

ADOLESCENT; ADULT; ANTIBODY AFFINITY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PHAGOCYTOSIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALE; MIDDLE AGED; OPSONIN PROTEINS; PHAGOCYTOSIS; PROTOZOAN PROTEINS; VACCINES, SYNTHETIC;

EID: 85032907197     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-08526-5     Document Type: Article

References (30)

1. Felgner, P. L. et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Scientific Reports 3, 3549, doi:10.1038/srep03549 (2013)
2. Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. Journal of Clinical Investigation: Insight 2, e89154, doi:10.1172/jci.insight.89154 (2017)
3. Ockenhouse, C. F. et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Journal of Infectious Diseases 177, 1664–1673 (1998)
4. Sedegah, M. et al. Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malaria Journal 12, 185, doi:10.1186/1475-2875-12-185 (2013)
5. Stoute, J. A. et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases 178, 1139–1144 (1998)
6. White, M. T. et al. The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLoS One 8, e61395, doi:10.1371/journal.pone.0061395 (2013)
7. Chaudhury, S. et al. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity. Malaria Journal 15, 301, doi:10.1186/s12936-016-1348-9 (2016)
8. Regules, J. A. et al. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. Journal of Infectious Diseases 214, 762–771, doi:10.1093/infdis/jiw237 (2016)
9. Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. The New England Journal of Medicine 336, 86–91, doi:10.1056/nejm199701093360202 (1997)
10. Chanput, W., Mes, J. M. & Wichers, H. J. THP-1 cell line: An in vitro cell model for immune modulation approach. International Immunopharmacology 23, 37–45 (2014)
11. Plotkin, S. A. Correlates of protection induced by vaccination. Clinical Vaccine Immunology 17, 1055–1065, doi:10.1128/CVI.00131-10 (2010)
12. Ockenhouse, C. F. et al. Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naive adults. PLoS One 10, e0131571, doi:10.1371/journal.pone.0131571 (2015)
13. Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Frontiers in Immunology 5, 520, doi:10.3389/fimmu.2014.00520 (2014)
14. Collins, A. M. & Jackson, K. J. A Temporal Model of Human IgE and IgG Antibody Function. Frontiers in Immunology 4, 235, doi:10.3389/fimmu.2013.00235 (2013)
15. de Boer, B. A., Kruize, Y. C., Rotmans, P. J. & Yazdanbakhsh, M. Interleukin-12 suppresses immunoglobulin E production but enhances immunoglobulin G4 production by human peripheral blood mononuclear cells. Infection and Immunity 65, 1122–5 (1997)
16. Chappel, J. A., Hollingdale, M. R. & Kang, A. S. IgG(4) Pf NPNA-1 a human anti-Plasmodium falciparum sporozoite monoclonal antibody cloned from a protected individual inhibits parasite invasion of hepatocytes. Human Antibodies 13, 91–96 (2004)
17. Duncan, E. H. & Bergmann-Leitner, E. S. Miniaturized Growth Inhibition Assay to Assess the Anti-blood Stage Activity of Antibodies. Methods in Molecular Biology (Clifton, N.J.) 1325, 153–165, doi:10.1007/978-1-4939-2815-6_13 (2015)
18. Bergmann-Leitner, E. S., Duncan, E. H. & Angov, E. in Malaria Parasites (ed Okwa O. O.) (InTech, 2012)
19. Mishra, S., Nussenzweig, R. S. & Nussenzweig, V. Antibodies to Plasmodium circumsporozoite protein (CSP) inhibit sporozoite’s cell traversal activity. Journal of Immunological Methods 377, 47–52, doi:10.1016/j.jim.2012.01.009 (2012)
20. Bergmann-Leitner, E. S. et al. Protective immune mechanisms against pre-erythrocytic forms of Plasmodium berghei depend on the target antigen. Trials in Vaccinology 3, 6–10 (2014)
21. Olivier, M., Gregory, D. J. & Forget, G. Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clinical Microbiology Reviews 18, 293–305, doi:10.1128/CMR.18.2.293-305.2005 (2005)
22. Kane, M. M. & Mosser, D. M. Leishmania parasites and their ploys to disrupt macrophage activation. Current Opinions in Hematolology 7, 26–31 (2000)
23. Mosser, D. M. & Edelson, P. J. The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. Nature 327, 329–331, doi:10.1038/327329b0 (1987)
24. Bertolino, P. & Bowen, D. G. Malaria and the liver: immunological hide-and-seek or subversion of immunity from within? Frontiers in Microbiology 6, 41, doi:10.3389/fmicb.2015.00041 (2015)
25. Usynin, I., Klotz, C. & Frevert, U. Malaria circumsporozoite protein inhibits the respiratory burst in Kupffer cells. Cellular Microbiology 9, 2610–2628, doi:10.1111/j.1462-5822.2007.00982.x (2007)
26. Ishino, T., Yano, K., Chinzei, Y. & Yuda, M. Cell-passage activity is required for the malarial parasite to cross the liver sinusoidal cell layer. PLoS Biology 2, E4, doi:10.1371/journal.pbio.0020004 (2004)
27. Tewari, K. et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 28, 7256–7266, doi:10.1016/j.vaccine.2010.08.098 (2010)
28. Kester, K. E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. Journal of Infectious Diseases 200, 337–346, doi:10.1086/600120 (2009)
29. Schwenk, R. et al. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. PLoS One 9, e111020, doi:10.1371/journal.pone.0111020 (2014)
30. Porter, M. D. et al. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clinical Vaccine Immunology 20, 803–810, doi:10.1128/CVI.00066-13 (2013)